Segments - Swine Healthcare Market by Products (Therapeutics [Feed Additives, Parasiticides, Vaccines, Anti-infectives, and Others] and Diagnostic Tests [Diagnostic Imaging, Rapid Immuno Migration (RIM), Polymerase Chain Reaction (PCR), Enzyme-linked Immunosorbent Assay (ELISA), Agar Gel Immuno- Diffusion (AGID), and Others]), Diseases (Swine Dysentery, Coccidiosis, Porcine Parvovirus, Respiratory Diseases, Exudative Dermatitis, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
The Global Swine Healthcare Market size was valued at USD 2.78 Billion in 2022 and is expected to surpass USD 5.29 Billion by 2031, expanding at a CAGR of 7.42% during the forecast period, 2023 – 2031. The growth of the market is attributed to the rising number of swine illnesses.
Swine health is linked to a variety of illnesses produced by pigs, as well as the development of treatments to treat these illnesses and diseases. Pig breeding can lead to a wide variety of illnesses, including fertility disorders and congenital abnormalities.
Pig farming is crucial to global food security, agricultural economies, and domestic and international trade. Infectious illnesses have an effect on pig health as well as the global swine sector's security and output.
As a result, government agencies are initiating efforts to safeguard and improve swine health, reducing the impact of swine infections on humans. As the welfare of the animal is so important to the production of high-quality livestock products, several suppliers are progressively using a wider range of medications to treat and prevent swine diseases.
Increasing R&D expenditures in the creation of innovative treatments are estimated to propel the market growth during the forecast period.
Rising various government activities aimed at preventing zoonotic illnesses are projected to spur the market expansion in the coming years.
Growing demand for animal products is a major factor fueling the market growth during the forecast period.
Government regulations prohibiting the use of medications in pigs are expected to hinder the market expansion.
Increasing public awareness of swine health-related goods and treatments is anticipated to offer significant opportunities for the market players.
The report on the global swine healthcare market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Swine Healthcare Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2022 |
Historic Data |
2016–2021 |
Forecast Period |
2023–2031 |
Segmentation |
Products (Therapeutics [Feed Additives, Parasiticides, Vaccines, Anti-infectives, and Others] and Diagnostic Tests [Diagnostic Imaging, Rapid Immuno Migration (RIM), Polymerase Chain Reaction (PCR), Enzyme-linked Immuno-Sorbent Assay (ELISA), Agar Gel Immuno- Diffusion (AGID), and Others]), and Diseases (Swine Dysentery, Coccidiosis, Porcine Parvovirus, Respiratory Diseases, Exudative Dermatitis, and Others) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
Huvepharma; Phibro Animal Health; IDEXX Laboratories Inc.; Zoetis Animal Healthcare; Virbac; Vetoquinol SA; Merck & Co Inc.; IDVet; Elanco; Ceva Animal Health Inc.; and Boehringer Ingelheim GmBH |
Based on products, the global swine healthcare market is segregated into therapeutics and diagnostic tests. The therapeutics segment is further divided into feed additives, parasiticides, vaccines, anti-infectives, and others. The diagnostic tests segment is further divided into diagnostic imaging, rapid immuno migration (RIM), polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), agar gel immuno- diffusion (AGID), and others.
The vaccines by therapeutics segment is expected to account for a key share of the market during the forecast period owing to vaccines are made up of destroyed or mutated viruses, bacteria, or other disease-causing microorganisms. As a result, they are unable to cause disease while also increasing immunity. New improved vaccinations including genetically modified components derived from those infectious pathogens have been developed. They are injected into pigs to induce an immune reaction that can protect the pigs from a future viral infection with the microorganism from which the vaccine was developed.
Alive vaccines contain life forms that proliferate in the pig, while inactivated vaccines include solely destroyed microorganisms that do not proliferate in the pig. Because there is a high demand for novel vaccines against all disease-causing microorganisms, R&D spending is rapidly increasing, enabling the vaccine segment to extend its reach to a wider range of ailments.
On the basis of diseases, the market is segmented into swine dysentery, coccidiosis, porcine parvovirus, respiratory diseases, exudative dermatitis, and others. The swine dysentery segment is expected to hold a key share of the market in the coming years due to diarrhea is a symptom of this illness in animals, and it can be present both with and without blood.
Brachyspira hyodsenteriae is the bacteria that causes it. Post-weaning pigs' growth rates are lowered, and in certain circumstances, they die suddenly. Antibiotics, either in feed, liquid, or intravenous, are used to treat the condition. Lowering grazing density in the herd can be a good method to reduce infection stress and pressure. Rat control is a key priority, in order to enhance cleanliness levels; rats are a carrier for this illness. As this is a primary channel of disease transmission, the plan for purchasing and delivering alternative stock should be examined.
On the basis of regions, the global swine healthcare market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market at healthy CAGR during the forecast period.
The regional market growth can be attributed to an increase in swine illnesses including porcine epidemic diarrhea (PEDv), swine enteric coronavirus diseases (SECD), and porcine delta coronavirus (PDCoV), that have caused serious morbidity and death, especially in young piglets. In North America, the virus is prevalent in swine communities. The Swine Health Protection Act (SHPA) governs the meat products given to pigs in the United States. This law assures that all food waste provided to pigs is appropriately handled to kill disease-causing germs.
Raw meat can cause a variety of infectious or contagious illnesses in pigs. With the increase in swine disease, the US is projected to be a prominent revenue-generating region for the swine health market during the forecast period.
The global swine healthcare market has been segmented based on
Key players competing in the global swine healthcare market include Huvepharma; Phibro Animal Health; IDEXX Laboratories Inc.; Zoetis Animal Healthcare; Virbac; Vetoquinol SA; Merck & Co Inc.; IDVet; Elanco; Ceva Animal Health Inc.; and Boehringer Ingelheim GmBH. Some of these players are adopting several business strategies including acquisitions, mergers, collaborations, partnerships, capacity expansion, and product launches to enhance their market shares.